Novel approaches to lipidlowering therapy
| Autor: | Frederick J. Raal, D Brozin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Mipomersen
lcsh:Medicine 030204 cardiovascular system & hematology Bioinformatics 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ezetimibe Cholesterylester transfer protein medicine 030212 general & internal medicine cardiovascular diseases lcsh:R5-920 biology medicine.diagnostic_test business.industry Cholesterol PCSK9 lcsh:R nutritional and metabolic diseases General Medicine chemistry biology.protein Apolipoprotein C3 lipids (amino acids peptides and proteins) Lipid profile business lcsh:Medicine (General) Lipoprotein medicine.drug |
| Zdroj: | South African Medical Journal, Vol 108, Iss 4, Pp 262-265 (2018) |
| ISSN: | 0256-9574 2078-5135 |
| Popis: | Cardiovascular disease (CVD) remains a major cause of death worldwide, with dyslipidaemia playing a significant role in the disease process. It is clinically useful to demarcate hypercholesterolaemia from hypertriglyceridaemia, with an increased serum low-density lipoprotein (LDL) cholesterol being the most powerful predictor of CVD morbidity and mortality, and a significant elevation in triglyceride levels increasing the risk of acute pancreatitis. Statins (with or without ezetimibe) and fibrates are the current first-line therapy in the management of dyslipidaemia. Although these medications have shown effectiveness in reducing CVD complications, there are patients who require a greater modification in lipid profile or are intolerant of first-line therapy. Novel agents are on the horizon, which have shown to lead to a significant decrease in serum LDL cholesterol. These include the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (which have shown a reduction in CVD morbidity), mipomersen, cholesterol ester transfer protein (CETP) inhibitors and bempedoic acid. Further studies of the clinical benefit of these medications are ongoing. Drugs such as pemfibrate, angiopoietin-like protein 3 (ANGPTL3) inhibitors, apolipoprotein C3 (apo C3) inhibitors and diacylglycerol acyltransferase-1 (DGAT 1) inhibitors have shown promising results in the management of hypertriglyceridaemia. It is hoped that these exciting new technological advancements in the future management of dyslipidaemia will result in clinical benefit for patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|